top of page

Brain cancer community gets help in accessing clinical trials

myTomorrows, a global health technology company connecting patients with all possible treatment options, today announced a new partnership with brainstrust, a UK-based charity that helps people living with a brain tumor reach their potential and thrive. Under the new partnership, people with brain tumors will be equipped with the means to bolster their knowledge of relevant treatment options, potentially extending to participation in clinical trials and access to pre-approval drugs. Moreover, the partnership provides a new layer of support to clinicians in their efforts to recruit patients to relevant clinical trials. There are 80,000 people living with a brain tumor in England alone, with a patient receiving a diagnosis every two hours. Brain tumors kill more children and adults under the age of 40 than any other cancer, and incidences and deaths from brain tumors are on the rise. With only 12% of brain tumor patients surviving beyond five years of their diagnosis, it is crucial for these patients to be as robustly and accurately informed as possible in their search for treatment options – especially when it comes to clinical trials, as it is often difficult to find and understand relevant information about them. brainstrust will now be able to provide its sizeable patient network with timely, up to date and useful information about credible and accessible clinical trials, with expert support from myTomorrows. myTomorrows‘ trained patient navigators will act as a single point of contact to guide patients with brain tumors, their loved ones, and healthcare professionals through the vast landscape of medical care and help them make the best possible decision during their treatment journey. „We are very excited to be partnering with brainstrust, which boasts years of experience supporting and educating patients with brain cancer about many different aspects of their disease. Our collaboration aims to empower these patients to navigate their treatment journeys with more confidence and options,“ said Michel van Harten, CEO of myTomorrows. „Collaborating with leading patient advocacy organizations like brainstrust allows myTomorrows to extend our reach to patients affected by numerous conditions. This partnership forms part of our overall mission to raise patients‘ and physicians‘ awareness of different treatment options while enabling pharmaceutical companies to expand access throughout the drug development cycle.“ „This is a very helpful and meaningful collaboration for the brain tumor community,“ said Helen Bulbeck, Director of Policy and Services, brainstrust. „This partnership means that people can build on the confidence and focus they have gained through their coaching with brainstrust and apply it to securing access to tangible options with the support of myTomorrows. People can be assured that they have turned every stone on their brain tumor journey and that they are working towards their best possible outcome.“ The myTomorrows platform offers access to clinical trial information that patients and their physicians can discuss thoroughly, weighing the risks and benefits, before deciding if applying for a clinical trial is right for them.

Aktuelle Beiträge

Alle ansehen

Appell des 44. DPT an Lauterbach

Zum Auftakt des 44. Deutschen Psychotherapeutentages (DPT), der am 12. und 13. April in Würzburg stattfindet, richten die Delegierten einen Appell an Bundesgesundheitsminister Prof. Dr. Lauterbach, di


bottom of page